Core Insights - The report highlights that the Beijing Stock Exchange (BSE) will fully enter the "920 era" on October 9, 2025, marking a significant milestone in its development as China's third-largest stock exchange [2][7][8] - The transition to the new 920 code for existing stocks aims to enhance stock identification and streamline trading processes, thereby solidifying BSE's independent status [5][7] - The report expresses optimism about the market's upward trend, driven by ongoing high-quality expansion, stock code transitions, and the issuance of specialized index funds and ETFs [2][10][11] Market Performance - The average daily trading volume for BSE stocks has decreased to 321 billion yuan, with the BSE 50 index experiencing a weekly decline of 1.07% [10][13] - The overall price-to-earnings (PE) ratio for BSE stocks has fallen to 54.76X, while the PE ratios for the ChiNext and STAR Market have increased [13][14] - The BSE 50 index reported a value of 1,600.88 points, reflecting a downward trend compared to previous weeks [14] New Listings and Adjustments - The report notes that 36 companies have been newly listed on the BSE from January 1, 2024, to September 12, 2025, with one new company, Sanxie Electric, listed in the latest week [19][20] - The BSE 50 index will undergo its third adjustment of the year on September 15, 2025, with four companies being added and four removed from the index [10][12] Investment Recommendations - The report suggests focusing on high-quality stocks with reasonable valuations that have not yet reached new highs, as well as stocks with strong industry themes [10][11] - Specific sectors to watch include stable growth companies, high-end manufacturing, overseas-related stocks, and consumer-related stocks [11][12]

Investment Rating - Investment rating: Positive (maintained) [4] Core Viewpoints - The report emphasizes the potential of PD1/VEGF/IL-2 mechanisms and suggests continued attention on Shanghai Yizhong [3][4] - The Chinese pharmaceutical industry has completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth curves for Chinese pharmaceutical companies [51][52] - The report highlights the importance of innovation in the pharmaceutical sector, with a focus on the growth of innovative drugs and the increasing ability of Chinese companies to expand internationally [51][52] Summary by Sections Market Performance - From September 8 to September 12, the pharmaceutical index rose by 1.03%, outperforming the CSI 300 index by 0.47% [5] - The number of stocks that rose this week was 263, while 220 stocks fell, with the top gainers being Zhend Medical (+41%) and Haooubo (+28%) [5][35] Investment Opportunities - Suggested stocks to watch include: 1) Innovative drugs: Xinlitai, Rejing Bio, Shanghai Yizhong, Kanghong Pharmaceutical, and others [5] 2) Companies with improving performance and low valuation: WuXi AppTec, Tigermed, and others [5] 3) Medical consumables and drug companies benefiting from marginal improvements in centralized procurement [5] Mechanism Insights - The report discusses the complementary mechanisms of PD1, VEGF, and IL-2, highlighting Shanghai Yizhong's YXC-001, which integrates these three targets into a single molecule, potentially offering significant advantages in efficacy and pharmacokinetics [3][30][34] Industry Trends - The report notes that the aging population and chronic disease demand are increasing, with a focus on cardiovascular, endocrine, and orthopedic diseases [51] - The payment side is also improving, with steady growth in medical insurance revenue and the promotion of commercial insurance [51] Future Outlook - The report anticipates a rebound in the pharmaceutical industry in 2025, driven by innovative drugs, with structural growth expected in specific sectors and stocks [51][52] - It suggests that the second half of 2025 will see a recovery in medical consumption and manufacturing performance, with a focus on low-valuation assets [52]

Group 1: Report Industry Investment Rating - The report is bullish on the bond market in the short - term [2] Group 2: Report's Core View - In August 2025, new loans increased significantly less year - on - year, and credit demand remained weak. The mortgage prepayment pressure may rise, and credit demand may be weak in the long - term. In September, banks may boost loan balance data through ultra - short - term loans, and new loans in October may be very low [2] - In recent years, individuals have deleveraged while enterprises have increased leverage, leading to rising corporate debt pressure. Personal consumption is sluggish, and corporate profitability is worrying [2] - In August, the M2 growth rate was flat month - on - month, and the M1 growth rate rebounded month - on - month. It is expected that the M1 growth rate will decline in the fourth quarter [2] - The social financing growth rate may have reached a stage peak. It is expected that new loans will increase less year - on - year in 2025, government bond net financing will expand significantly year - on - year, and the social financing growth rate may rise first and then fall, reaching about 8.1% at the end of the year [2] - The 10 - year government bond may have allocation value for bank self - operations. It is expected that the yield of the 10 - year Treasury bond will be between 1.6% - 1.8% in the second half of the year [2] Group 3: Summary by Related Catalog Credit Data - On September 12, 2025, the central bank disclosed that in August, new loans were 59 billion yuan, and social financing was 2.57 trillion yuan. At the end of August, M2 reached 332.0 trillion yuan, a year - on - year increase of 8.8%; M1 increased by 6.0% year - on - year; the social financing growth rate was 8.8% [1] - In August, new loans increased 31 billion yuan less year - on - year. Personal loans increased 3.03 billion yuan, including 1.05 billion yuan in short - term personal loans and 2 billion yuan in medium - and long - term personal loans, a significant year - on - year decrease. Corporate short - term loans increased 7 billion yuan, corporate medium - and long - term loans increased 47 billion yuan, and bill financing increased 5.31 billion yuan [2] Leverage and Financial Situation - As of the end of August 2025, the ratio of personal loans to deposit balances was only 52.7%, a decrease of 17.6 percentage points compared with the end of May 2022. Since 2021, the difference between personal deposits and loans has increased significantly, while that of corporate has decreased significantly [2] Monetary Supply - The central bank has used the new M1 caliber since January 2025. As of the end of August 2025, the new M1 balance was 111.2 trillion yuan, a decrease of 76.9 billion yuan from the beginning of the year. The M2 growth rate in August was 8.8%, flat month - on - month [2] Social Financing - In August, the social financing increment was 2.57 trillion yuan, a year - on - year decrease of 0.46 trillion yuan. The decrease mainly came from credit and government bond net financing. The social financing growth rate at the end of August was 8.8%, a decrease of 0.2 percentage points from the end of the previous month [2] - It is predicted that in 2025, social financing will be 34.6909 trillion yuan, with new loans of 16.28 trillion yuan, a decrease of 76.95 billion yuan year - on - year; government bond net financing of 13.77 trillion yuan, an increase of 247.46 billion yuan year - on - year [22]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance in H1 2025 met expectations, with the launch of methylphenidate officially underway [5] - The company is positioned to benefit from the growing demand for high-end controlled-release narcotic drugs, particularly methylphenidate and oxycodone, which are expected to see continued volume growth [7] - The company is increasing its R&D investment, focusing on self-developed and collaborative projects in various therapeutic areas [7] Financial Summary - For H1 2025, the company achieved revenue of 732 million yuan, a year-on-year decline of 4.80%, while net profit attributable to the parent company was 90 million yuan, a year-on-year increase of 16.53% [7] - The company's gross margin and net profit margin for H1 2025 were 64.25% and 12.32%, respectively, with a year-on-year change of -7.28% and +2.26 percentage points [7] - Revenue projections for 2025-2027 are 1.688 billion yuan, 2.009 billion yuan, and 2.385 billion yuan, with corresponding year-on-year growth rates of 11.16%, 19.01%, and 18.74% [6][8] - The forecasted net profit for 2025-2027 is 209 million yuan, 265 million yuan, and 340 million yuan, with year-on-year growth rates of 30%, 26.69%, and 28.54% [6][8] Market Position and Product Pipeline - The company has a leading position in the high-tech permeation pump controlled-release technology field, with several products already launched [7] - The newly launched methylphenidate controlled-release tablets are expected to achieve rapid market penetration due to the growing prevalence of ADHD among children and adolescents in China [7] - The oxycodone controlled-release tablets are projected to maintain rapid growth, with expected sales exceeding 100 million yuan in their first full year of sales [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company reported a significant increase in revenue and net profit for the first half of 2025, with revenue growing by 26.0% to 70 billion and net profit increasing by 33.5% to 14.8 billion [3] - The contribution of new business value (NBV) from bancassurance exceeded 50%, indicating a stable trend in the individual insurance sales force [4][6] - Investment performance has been strong, with a notable increase in investment income, which is crucial for the company's overall performance [5][6] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a 58.4% growth in NBV, driven by a 65% increase in first-year premiums and a 353% increase in single premiums [6] - Total investment return rate and comprehensive investment return rate were reported at 5.9% and 6.3%, respectively [3] Profit Forecast and Valuation - The company is expected to achieve net profits of 29.7 billion, 28.6 billion, and 30.3 billion for the years 2025 to 2027, with growth rates of 13.3%, -3.7%, and 6.1% respectively [8] - The estimated intrinsic value per share for 2025-2027 is projected to be 92.8, 101.6, and 111.7 yuan, with current price-to-embedded value (P/EV) ratios of 0.68, 0.62, and 0.57 [8] Investment Strategy - The company is focusing on enhancing its bancassurance channel by increasing cooperation with more banks, which is expected to boost its performance [6] - The individual insurance sales force has shown signs of stabilization, with a significant increase in qualified personnel [6][12]

Investment Rating - The investment rating for China Pacific Insurance is "Buy" (maintained) [5] Core Views - China Pacific Insurance reported a strong performance in its 2025 mid-year report, with revenue and net operating profit increasing by 3.0% and 7.1% year-on-year to 200.5 billion and 19.9 billion respectively. The net profit attributable to shareholders grew by 11% to 27.9 billion, driven by underwriting profits from property insurance and group investment income [6][12] - The life insurance segment showed robust growth, with new business value (NBV) increasing by 32.3% year-on-year in the first half of 2025, primarily supported by the bancassurance channel, which saw a 58.6% increase in new policies [6][12] Summary by Sections Market Performance - The closing price as of September 11, 2025, was 38.14 yuan, with a market capitalization of approximately 366.92 billion [3] Financial Data - Total assets are projected to reach approximately 3,291.85 billion by 2025, with total liabilities at around 2,948.76 billion [21] - The company’s debt-to-asset ratio stands at 89.66% [3] Life Insurance Business - The life insurance segment's net profit growth was 3.6%, contributing 72.8% to the total net profit. The segment's comprehensive solvency ratio improved to 215% by June 2025 [9][12] - The bancassurance channel's contribution to NBV reached 37.8%, indicating strong growth potential in this area [9] Property Insurance Business - The comprehensive cost ratio for property insurance decreased by 0.8 percentage points to 96.3%, attributed to stricter regulations and a focus on high-quality development [9] Investment Business - The investment strategy emphasizes a balanced approach between long-duration bonds and high-growth equity assets, with total investment income decreasing slightly due to market fluctuations [12] - The establishment of new investment funds aims to enhance alternative investment opportunities, with targeted sizes of 30 billion and 20 billion for the respective funds [12] Earnings Forecast and Valuation - Projected net profits for 2025-2027 are 48.1 billion, 55.2 billion, and 64.4 billion respectively, with corresponding growth rates of 6.9%, 14.8%, and 16.6% [12] - The price-to-embedded value (P/EV) ratio is expected to decline from 0.58 in 2025 to 0.46 in 2027, indicating a favorable valuation outlook [12]

Investment Rating - The investment rating for Shandong Expressway is "Buy" (maintained) [6] Core Views - The company is expected to strengthen its road asset scale and achieve steady growth in performance [6] - The company reported a revenue of 10.739 billion yuan in the first half of 2025, a year-on-year decrease of 11.52%, while the net profit attributable to shareholders was 1.696 billion yuan, an increase of 3.89% [8] - The revenue from toll road operations remained stable, contributing to performance growth despite a decline in construction service income [8] Summary by Sections Market Performance - Closing price as of September 11, 2025, was 9.11 yuan, with a market capitalization of 44,042.94 million yuan [4] Financial Data - Total assets amounted to 161,688 million yuan, with a debt-to-asset ratio of 65.96% [4] - Earnings per share (EPS) for 2025 is projected at 0.67 yuan [7] Revenue and Profit Forecast - Revenue forecast for 2025 is 28,471 million yuan, with a slight year-on-year decrease of 0.08% [7] - Net profit attributable to shareholders is expected to be 3,215 million yuan in 2025, reflecting a growth of 0.59% [7] Operational Highlights - The company is actively enhancing its road asset scale and optimizing its highway network layout, with ongoing projects expected to contribute to future revenue [8] - The gross profit margin for the first half of 2025 was 34.44%, showing a year-on-year increase of 5.66 percentage points [8]

Fixed Income - The overall price level remains low, with CPI and PPI both in negative territory. In August, CPI decreased by 0.4% year-on-year, while PPI's decline narrowed to 2.9%, marking the first contraction since February this year [3][8][10] Pharmaceutical Industry - The pharmaceutical industry is expected to stabilize in the second half of 2024 and H1 2025, with a focus on innovative drugs. In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8% [12][13][14] - Innovative drug companies reported a revenue of 26.964 billion yuan in H1 2025, up 11.78% year-on-year, indicating a strong growth momentum [14] - The medical device sector faced challenges, with H1 2025 revenue down 5.32% year-on-year, while the biopharmaceutical sector showed mixed results, with blood products revenue down 1.4% and vaccine revenue down 45.3% [15][16][20] Real Estate - The real estate sector saw a decline of 1.5% this week, with new home sales in 42 key cities dropping by 15.3% week-on-week. The government is implementing policies to support housing, including adjustments to mortgage rates and public housing fund policies [22][23][24] - The Ministry of Housing and Urban-Rural Development emphasized high-level legislation to promote quality development in housing and urban construction [24][25] Public Utilities and Environmental Protection - Huadian International reported a revenue of 60 billion yuan in H1 2025, a decrease of 8.98% year-on-year, while net profit increased by 13.15% to 3.904 billion yuan. The company benefited from lower coal prices and stable electricity prices [26][27][28] Transportation - China Ship Leasing achieved a revenue of 2.018 billion HKD in H1 2025, a year-on-year increase of 2.7%. However, net profit decreased by 16.7% due to tax adjustments and reduced rental income from joint ventures [31][32][33] - The shipping market is expected to see increased demand for leasing due to environmental policies and aging fleets, which may benefit the company in the long term [33] Electronics - Seiyun Circuit, a leading PCB manufacturer, reported a revenue of 5.022 billion yuan in 2024, up 11.13% year-on-year, with a net profit of 675 million yuan, marking a 36.17% increase [36][37] - The demand for AI servers is rapidly expanding, with the global AI server market projected to grow significantly, benefiting PCB manufacturers [37][38] Food Industry - Gais Food, a leader in the prepared vegetable market, aims to issue convertible bonds to expand production capacity. The prepared vegetable market in China is expected to exceed 600 billion yuan by 2025, driven by both B2B and B2C demand [40][41]

Investment Rating - The investment rating for the company is "Buy" (maintained) due to smooth commercialization progress and further updates on HARMONi data [5]. Core Views - The company reported a revenue of 1.412 billion RMB in H1 2025, representing a year-on-year increase of 37.75%, with a net profit attributable to shareholders of -570 million RMB [7]. - The commercialization of key products, namely Cadonilimab and Ivosidenib, has driven revenue growth, with product sales revenue increasing by 49.20% year-on-year [7]. - The HARMONi study presented at the WCLC 2025 conference showed improved overall survival (OS) data, with an OS hazard ratio (HR) of 0.78, indicating significant survival benefits [7]. - The company is expected to achieve revenues of 34.19 billion RMB, 55.98 billion RMB, and 85.77 billion RMB for the years 2025 to 2027, respectively [7]. Financial Summary - Revenue projections for 2023, 2024, 2025E, 2026E, and 2027E are 4,526 million RMB, 2,124 million RMB, 3,419 million RMB, 5,598 million RMB, and 8,577 million RMB, respectively, with corresponding growth rates of 440.3%, -53.1%, 61.0%, 63.7%, and 53.2% [6]. - The net profit attributable to shareholders is projected to be 2,028.30 million RMB in 2023, -514.52 million RMB in 2024, -29.64 million RMB in 2025E, 586.11 million RMB in 2026E, and 1,485.85 million RMB in 2027E, with growth rates of 273.6%, -125.4%, 94.2%, 2077.2%, and 153.5% respectively [6]. - The company's reasonable equity value is estimated at 187.5 billion HKD, assuming a perpetual growth rate of 3% and a WACC of 7.06% [7].

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Viewpoints - The pharmaceutical industry is experiencing significant differentiation, with innovative drugs, raw materials, and CXO sectors performing well [2][3] - The overall performance of the pharmaceutical industry in 2024 and the first half of 2025 is under pressure, with notable declines in consumer segments, while innovative drugs, raw materials, and CXO show strong growth [2] Summary by Relevant Sections Overall Industry Performance - In 2024, 453 pharmaceutical companies achieved revenue of 2.46 trillion yuan, a year-on-year decline of 0.55%, and a net profit of 148.65 billion yuan, down 8.8%. In the first half of 2025, revenue was 1.22 trillion yuan, a decrease of 2.5%, with net profit at 102 billion yuan, down 2.1% [2][68] Innovative Drugs - In the first half of 2025, innovative drug companies generated revenue of 26.964 billion yuan, a year-on-year increase of 11.78%. Domestic innovative drug companies are transitioning from R&D to commercialization, marking a turning point towards profitability [2][10] Chemical Drugs - Chemical drug companies reported revenue of 198.06 billion yuan in the first half of 2025, a decline of 3.83%, with net profit at 22.14 billion yuan, down 0.11%. Traditional generic to innovative drug companies are performing better [2][10] Medical Devices - Medical device companies achieved revenue of 106.82 billion yuan in the first half of 2025, down 5.32%, with net profit at 17.58 billion yuan, down 18.07%. The sector is under pressure due to inventory and policy impacts, but high-value consumables are showing better performance [2][10] Biological Products - Blood products revenue in 2024 was 24.18 billion yuan, down 1.4%, with net profit of 6.23 billion yuan, up 14.47%. Vaccine companies faced significant declines, with 2024 revenue at 40.77 billion yuan, down 45.3% [2][10] Traditional Chinese Medicine - In the first half of 2025, traditional Chinese medicine companies reported revenue of 174.38 billion yuan, down 4.57%, with net profit of 22.48 billion yuan, up 0.70%. The sector is under pressure from regulatory policies and weak consumer demand [2][10] Raw Materials - Raw material companies achieved revenue of 47.86 billion yuan in the first half of 2025, down 2.90%, but net profit increased by 20.61% to 8.10 billion yuan. High-demand segments like peptides are performing well [2][10] Pharmaceutical Commerce - Pharmaceutical commerce companies reported revenue of 517.86 billion yuan in the first half of 2025, flat year-on-year, with net profit of 12.09 billion yuan, up 7.6% [5] Medical Services - Medical service companies achieved revenue of 36.36 billion yuan in the first half of 2025, down 4.93%, with net profit of 2.35 billion yuan, down 11.17% [5] CXO & Research Services - The CXO and research services sector reported revenue of 50.64 billion yuan in the first half of 2025, up 13.05%, with net profit of 11.91 billion yuan, up 60.6% [5]